Tourmaline Bio, Inc.
TRMLDelisted Oct 28, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001827506
Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.
Q1 2024 vs. Q4 2023
How the institutions holding Tourmaline Bio, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 54 | 96 | +42 |
| Shares | 13.0M | 20.6M | +7.55M (+58.0%) |
| Value | $338.2M | $469.9M | +$131.7M (+38.9%) |
New holders (50)
Institutions that held Tourmaline Bio, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (8)
Institutions that held Tourmaline Bio, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Great Point Partners LLC | 672,885 | $17.6M |
| BML Capital Management, LLC | 245,500 | $6.43M |
| EAM Investors, LLC | 24,585 | $643.6K |
| Cubist Systematic Strategies, LLC | 15,241 | $399.0K |
| Jump Financial, LLC | 14,500 | $379.6K |
| 683 Capital Management, LLC | 13,356 | $349.7K |
| ExodusPoint Capital Management, LP | 10,650 | $279.0K |
| Point72 Middle East FZE | 1,040 | $27.2K |